Updated June 24, 2013
The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) have developed an evidence-based guideline which establishes recommendations for EGFR and ALK testing, helping to guide targeted therapies. The guideline was released on April 3, 2013, in Archives of Pathology & Laboratory Medicine, Journal of Thoracic Oncology, and The Journal of Molecular Diagnostics.
The guideline provides answers to these important clinical questions:
- When should testing be performed?
- How should EGFR testing be performed?
- How should ALK testing be performed?
- Should other genes be routinely tested in lung cancer?
- How should molecular testing of lung cancer be implemented?
The implementation of the CAP/IASLC/AMP guideline will ensure a uniform approach to the molecular testing of lung cancer and will improve the effectiveness of lung cancer treatment for patients.
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
Detailed information regarding the project’s comprehensive literature review, evidence grading and conflict of interest policy, etc., may be accessed in the Supplemental Digital Content available online within the manuscript.
Summary of Recommendations
Listen to the Archived April 24, 2013 Webcast with the Lead Authors of the Guideline
See Frequently Asked Questions (PDF, 73 KB) for further information.
Read the CAP TODAY Article on “New guidance on lung cancer testing”
Read the Patient Guide (PDF, 368 KB) for further information.
Comment on the Recommendations